

## Genetic associations between SGLT2 inhibition, DPP4 inhibition or GLP1R agonism and prostate cancer risk: a two-sample Mendelian randomisation study

Lin Shen MD <sup>1\*</sup>, Yifan Yang PhD <sup>2\*</sup>, Lei Lu PhD <sup>3</sup>, Oscar Hou In Chou MBBS MSc <sup>4</sup>,  
Quinncy Lee DrPH <sup>5</sup>, Tong Liu MD PhD <sup>6</sup>, Guoliang Li MD PhD <sup>7</sup>, Shuk Han Cheng PhD <sup>8</sup>,  
Gary Tse MD PhD FRCP FRCPath <sup>6,9,10<sup>κ</sup></sup>, Jiandong Zhou PhD <sup>11,12,13<sup>^</sup></sup>

<sup>1</sup> Department of Gastroenterology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China

<sup>2</sup> School of Management, Xi'an Jiaotong University, Xi'an, China

<sup>3</sup> Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, United Kingdom

<sup>4</sup> Division of Clinical Pharmacology, Department of Medicine, University of Hong Kong, Hong Kong, China

<sup>5</sup> Cardiovascular Analytics Group, PowerHealth Research Institute, Hong Kong, China

<sup>6</sup> Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China

<sup>7</sup> Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, 277 Yanta West Road, Xi'an, China

<sup>8</sup> Department of Biomedical Science, City University of Hong Kong, Kowloon, Hong Kong, China

<sup>9</sup> School of Nursing and Health Sciences, Hong Kong Metropolitan University, Hong Kong, China

<sup>10</sup> Kent and Medway Medical School, Canterbury Christ Church University and University of Kent, Canterbury, United Kingdom

<sup>11</sup> Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

<sup>12</sup> School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

<sup>13</sup> Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, China

\* Co-first author

<sup>^</sup> Correspondence to:

Prof. Gary Tse, MD, PhD, FRCP, FRCPath

School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, China

Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China

Kent and Medway Medical School, Canterbury, United Kingdom

Email: garytse86@gmail.com; gary.tse@kmmms.ac.uk; gatse@hkmu.edu.hk

Prof. Jiandong Zhou, PhD

Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

Email: [jdzhou@hku.hk](mailto:jdzhou@hku.hk)

## Abstract

**Background:** Epidemiological studies have linked the use of the anti-diabetic medications, sodium-glucose co-transporter-2 inhibitors (SGLT2I), dipeptidyl peptidase-4 inhibitors (DPP4I) and glucagon-like peptide-1 receptor agonists (GLP1RA), with prostate cancer risk. However, these studies cannot infer causality.

**Methods:** This was a two-sample Mendelian randomization (MR) using genome-wide association study data designed to identify causal relationships between SGLT2I, DPP4I or GLP1RA and prostate cancer. Genetic associations with HbA1c and risk of prostate cancer were extracted from IEU Open-GWAS Project database with GWAS id ukb-d-30750\_irmt (UK Biobank cohort) and ebi-a-GCST006085 (European Molecular Biology Laboratory's European Bioinformatics Institute cohort), respectively. The two GWAS datasets chosen were obtained from individuals of European ancestry to minimise potential bias from population stratification. The encoding genes targeted by SGLT2I, DPP4I and GLP1RA were SGC5A2, DPP4 and GLP1R, located in Chr16: 31494323-31502181, Chr2: 162848755-162930904 and Chr6: 39016557-39059079, respectively.

**Results:** A total of 31, 2 and 5 single nucleotide variants (SNVs) were used for SGC5A2, DPP4 and GLP1R. Our MR analysis results supported a causal relationship between genetic variation in SLC5A2 and DPP4 and reduced risk of prostate cancer at the Bonferroni-corrected threshold, with odds ratios (OR) [95% confidence intervals] of 0.47 [0.38-0.58] and 0.35 [0.24-0.53], but not for GLP1R (OR: 1.39 [0.93-2.07]). Sensitivity analyses by the leave-one-out method did not significantly alter the OR for SGLT2I.

**Conclusions:** The two-sample MR analysis found that SGLT2 and DPP4 inhibition, but not GLP1R agonism, was associated with lower risks of developing prostate cancer.

## Introduction

Diabetes mellitus is a common metabolic disorder, predisposing affected individuals to adverse cardiovascular events <sup>1</sup>, macro- and micro-vascular complications <sup>2</sup>, and cancer <sup>3</sup>. Whilst achieving good glycaemic control does not appear to reduce the risk of most cancer types <sup>4</sup>, different anti-diabetic medications may nevertheless modulate cancer risk. These medications may exert anti-cancer effects that may be independent of their actions on glucose control, acting via anti-inflammatory, anti-oxidative and hormonal or other cellular pathways <sup>5</sup>. Common second line medications include sodium-glucose co-transporter-2 inhibitors (SGLT2I), dipeptidyl peptidase 4 inhibitors (DPP4I) and glucagon-like peptide-1 receptor agonists (GLP1RA) and their use has been associated with altered risks of overall cancer <sup>6</sup>, as well as individual subtypes of colorectal <sup>7</sup>, gastric <sup>8</sup>, hepatocellular <sup>9</sup> and prostate <sup>10</sup> cancer. However, such epidemiological studies are susceptible to problems such as confounding and reversed causality. These can be addressed by applying Mendelian randomisation (MR), which uses genetic variants as instrumental variables (IVs) to quantify causal effects between exposures and outcomes.

## Methods

The two-sample MR framework was used to investigate the effects of genetic variants in the SGLT2I, DPP4I and GLP1RA targets on the risk of prostate cancer. Our team has previously used MR to evaluate the causality between different exposures and risks of adverse outcomes <sup>11,12</sup>. Due to the unavailability of GWAS data on the exposure (protein targets of antidiabetic drugs) and considering that lowering of glycated haemoglobin (HbA1c) level is a physiological response to antidiabetic drug, HbA1c was used. Genetic associations with HbA1c and risk of prostate cancer were extracted from IEU Open-GWAS Project database with GWAS id ukb-d-30750\_irt (UK Biobank cohort) and ebi-a-GCST006085 (European Molecular Biology Laboratory's European

Bioinformatics Institute cohort), respectively. The two GWAS datasets chosen were obtained from individuals of European ancestry to minimise potential bias from population stratification.

The IVs were screened for the genes that encode antidiabetic drug target proteins. Variations within and around these genes were used to assess the effects of drug use on exposure and outcomes. The detailed information about the protein targets and encoding genes for SGLT2I, DPP4I, and GLP1RA is provided in **Table 1**. SNVs within each encoding gene (within  $\pm 100$ kb base pairs of the gene location) were identified. Variants with p-values greater than  $5 \times 10^{-4}$  and a minor allele frequency (MAF) below 0.01 in the GWAS data for HbA1c were excluded. The remained variants for each antidiabetic drug target were selected as IVs and clumped with an  $R^2$  of 0.8, a window size of 250 kb, and the reference population set to EUR.

To ensure the validity of the MR analyses, three conditions must be satisfied<sup>13</sup>. 1) Relevance: the IVs are associated with the risk factor of interest. It was achieved by selecting IVs with a F-statistic  $> 10$ , 2) Independence, the IVs do not share common cause with the outcome. This was fulfilled by random assortment of genetic variants during conception. 3) Exclusion restriction, where IVs do not affect outcomes except through the risk factor. This assumption was tested by Cochran Q test, exclusion restriction, which evaluates heterogeneity. Evaluation of horizontal pleiotropy was conducted using the MR Egger method.

In instances where all three assumptions were met, the Inverse Variance Weighted (IVW) method was applied to yield unbiased estimates on the associations between exposures and outcomes. The F-statistic is calculated by dividing the square of beta by the square of the standard error, where an F-statistic  $> 10$  indicated sufficient instrument strength. Following Bonferroni correction, the significance level of multiple testing for 3 drugs classes was set as  $P < 0.017$  ( $0.05/3$ ).

The leave-one-out method was selected for sensitivity analysis, which entailed systematically excluding each variant within the drug's target gene region and subsequently calculating the meta-

effects of the remaining variants. The absence of statistically significant changes in MR estimates following the removal of each variant implies the robustness of the obtained results. All analyses were performed in R (Version 4.3.1), using the TwoSampleMR (Version: 0.5.7) package.

## Results

For the primary analysis, 31 variants were selected for SGLT2 inhibition (mean F-statistic of 27), 2 for DPP-4 inhibition (mean F-statistic of 17), and 25 for GLP-1 agonism (mean F-statistic of 20). Detailed data of the IVs to proxy antidiabetic drugs are shown in **Table 2**. The results of the MR analyses are shown in **Figure 1**. SGLT2I, as reflected by genetic variations in SLC5A2, led to reduced risks of prostate cancer at the Bonferroni-corrected threshold (odds ratio [OR] = 0.47, 95% CI 0.38-0.58). DPP4 inhibition also led to reduced risks of prostate cancer (OR = 0.35, 95% CI 0.24-0.53). However, no significant protective effect was observed for GLP1R agonism (OR: 1.39 [0.93-2.07]). No heterogeneity or pleiotropy was detected within the IVs in SLC5A2 and DPP4 analysis (**Figure 1**). More details on the MR analysis can be found in **Table 3**. Sensitivity analysis using the leave-one-out was performed for the genetic variations in SLC5A2 and the risk of prostate cancer. The analyses demonstrated the robustness of the results, indicating that after excluding each SNV, the overall error lines showed minimal changes (**Figure 2**). However, due to the insufficient genetic variants identified for DPP4, sensitivity analysis was not performed.

## Discussion

The present two-sample MR study found a significant association between genetic variation in SLC5A2 and DPP4 with prostate cancer. Thus, this study provides evidence that SGLT2 and DPP4 inhibition is protective against prostate cancer. They may directly on the prostate with glycaemic-independent effects. Such findings support possible drug repurposing of SGLT2I and

DPP4I on prostate cancer by making use of their pleiotropic effects<sup>14-16</sup>. Interests in this area was prompted largely due to the fact that cancer cells utilise glucose rather than fatty acids as a primary source of fuel<sup>17</sup>. Moreover, SGLT2I usage may inhibit the AMPK/mTOR pathway and induce apoptosis of cancerous cells<sup>18</sup>. SGLT2 inhibition has been shown to reduce glucose uptake and tumour progression in a xenograft model<sup>19</sup>. SGLT2I inhibited the clonogenic survival of prostate cancer cells<sup>20</sup>. In our study, the protective effects of SGLT2I were significant amongst patients without comorbidities but not those with prior comorbidities (heart failure, prior acute myocardial infarction, atrial fibrillation, peripheral vascular diseases). Whilst this could be explained by the limited sample size in the subgroups, we may also hypothesise that this could be explained partially by the SGLT2 expression level, as systemic diseases were suggested to increase the expression and activity of SGLT2<sup>21</sup>.

Our findings from MR on the protective effects of SGLT2 and DPP4 inhibition on the risks of developing prostate cancer amongst T2DM patients agree with those from other MR studies or observational studies. Regarding SGLT2I, a recent study by our team found that SGLTI use was associated with 55% lowered risk of prostate cancer development compared to DPP4I<sup>10</sup>. The effect estimate is similar in magnitude to the OR of 0.47 calculated from the MR analyses. For DPP4I, saxagliptin is linked to lower prostate cancer risk compared to sulfonylurea use<sup>22</sup>. In another observational study, sitagliptin was associated with lower risks of prostate cancer amongst Asians with an odd ratio of 0.61<sup>23</sup>. Such observations are in line with OR of 0.35 for DPP4I. Regarding GLP1R agonists, previous MR analyses found neutral effects on different cancer types including ovarian, lung and thyroid cancers<sup>24</sup>. Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial revealed that malignant prostate neoplasms were present in a lower proportion of diabetic patients who use liraglutide compared to the placebo group<sup>25</sup>. In a nationwide register-based cohort study from Denmark, GLP1RA use was inversely associated with prostate cancer risk compared to basal insulin use<sup>26</sup>.

## Limitations

Several limitations of this study should be noted. Firstly, the MR analysis was conducted using European populations, which the genetic association might be different from the Hong Kong population in the drug cohort. Lastly, the retrospective design of our study necessitates the presentation of associations but not causal links between SGLT2I versus DPP4I use and the risk of new-onset prostate cancer. Therefore, further research is warranted to explore the beneficial effects of SGLT2I.

## Conclusions

The two-sample MR analysis found that SGLT2 and DPP4 inhibition, but not GLP1R agonism, was associated with lower risks of developing prostate cancer.

## References

1. Ahmad A, Lim LL, Morieri ML, et al. Precision prognostics for cardiovascular disease in Type 2 diabetes: a systematic review and meta-analysis. *Commun Med (Lond)* 2024;4:11.
2. Shi Y, Vanhoutte PM. Macro- and microvascular endothelial dysfunction in diabetes. *J Diabetes* 2017;9:434-49.
3. Chen Y, Mushashi F, Son S, Bhatti P, Dummer T, Murphy RA. Diabetes medications and cancer risk associations: a systematic review and meta-analysis of evidence over the past 10 years. *Sci Rep* 2023;13:11844.
4. Dankner R, Boker LK, Boffetta P, et al. A historical cohort study on glycemic-control and cancer-risk among patients with diabetes. *Cancer Epidemiol* 2018;57:104-9.
5. Olatunde A, Nigam M, Singh RK, et al. Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs. *Cancer Cell Int* 2021;21:499.
6. Chung CT, Lakhani I, Chou OHI, et al. Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in Type 2 diabetes mellitus: A population-based study. *Cancer Med* 2023;12:12299-315.
7. Chan RNC, Chan RNF, Chou OHI, Tse G, Lee S. Lower risks of incident colorectal cancer in SGLT2i users compared to DPP4i users: A propensity score-matched study with competing risk analysis. *Eur J Intern Med* 2023;110:125-7.

8. Chou OHI, Chauhan VK, Chung CTS, et al. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study. *Gastric Cancer* 2024;27:947-70.
9. Chou OHI, Ning J, Chan RNC, et al. Lower Risks of New-Onset Hepatocellular Carcinoma in Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors Versus DPP4 Inhibitors. *J Natl Compr Canc Netw* 2024;22.
10. Chou OHI, Lu L, Chung CT, et al. Comparisons of the risks of new-onset prostate cancer in type 2 diabetes mellitus between SGLT2I and DPP4I users: a population-based cohort study. *Diabetes Metab* 2024:101571.
11. Zhang N, Jia Z, Gu T, et al. Associations between modifiable risk factors and frailty: a Mendelian randomisation study. *J Epidemiol Community Health* 2023;77:782-90.
12. Li X, Chan JSK, Guan B, et al. Triglyceride-glucose index and the risk of heart failure: Evidence from two large cohorts and a mendelian randomization analysis. *Cardiovasc Diabetol* 2022;21:229.
13. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *BMJ* 2018;362:k601.
14. Lu Z, Qi L, Bo XJ, Liu GD, Wang JM, Li G. Expression of CD26 and CXCR4 in prostate carcinoma and its relationship with clinical parameters. *J Res Med Sci* 2013;18:647-52.
15. Bekele K, Smith T, Stewart L. The SGLT2 Inhibitor Canagliflozin Reduces Androgen Receptor Expression and Nuclear Localization of Beta-Catenin in Human Prostate Cancer Cells. 2022.
16. Benedetti R, Benincasa G, Glass K, et al. Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials. *Pharmacological Research* 2022;175:106039.
17. Nakano D, Kawaguchi T, Iwamoto H, Hayakawa M, Koga H, Torimura T. Effects of canagliflozin on growth and metabolic reprogramming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT). *PLoS One* 2020;15:e0232283.
18. Zhou J, Zhu J, Yu SJ, et al. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway. *Biomed Pharmacother* 2020;132:110821.
19. Scafoglio C, Hirayama BA, Kepe V, et al. Functional expression of sodium-glucose transporters in cancer. *Proceedings of the National Academy of Sciences* 2015;112:E4111-E9.
20. Villani LA, Smith BK, Marcinko K, et al. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. *Molecular metabolism* 2016;5:1048-56.
21. Wilcox CS. Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors. *Hypertension* 2020;75:894-901.
22. Lu S, Yin H, Yu OHY, Azoulay L. Incretin-Based Drugs and the Incidence of Prostate Cancer Among Patients With Type 2 Diabetes. *Epidemiology* 2022;33:563-71.
23. Tseng CH. Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes. *Oncotarget* 2017;8:19057-64.
24. Sun Y, Liu Y, Dian Y, Zeng F, Deng G, Lei S. Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials. *Int J Surg* 2024;110:4688-94.
25. Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB. Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. *Diabetes Care* 2018;41:1663-71.
26. Skriver C, Friis S, Knudsen LB, et al. Potential preventive properties of GLP-1 receptor agonists against prostate cancer: a nationwide cohort study. *Diabetologia* 2023;66:2007-16.





## Tables

**Table 1. Detailed information of the different anti-diabetic drug classes, targets, and encoding genes.**

Drug class	Drug target ( <i>Encoding gene</i> )	Gene region
Sodium-glucose cotransporter 2 (SGLT2) inhibitors	SGLT2 ( <i>SGC5A2</i> )	Chr16: 31494323-31502181
Dipeptidyl peptidase 4 (DPP-IV) inhibitors	DPP-IV ( <i>DPP4</i> )	Chr2: 162848755-162930904
Glucagon-like peptide 1 (GLP1) agonists	GLP-1R ( <i>GLP1R</i> )	Chr6: 39016557-39059079

**Table 2. Genetic variants used as instrumental variables for different antidiabetic drug targets for the primary analysis.**

EA/OA, effect allele/other allele; MAF, minor allele frequency.

Target	SNP	EA/OA	MAF	Beta	SE	P-value	F
SGLT2	rs140154847	G/T	0.0151	0.0457	0.0099	3.66E-06	21
SGLT2	rs8050500	C/T	0.4460	-0.0266	0.0023	1.15E-30	121
SGLT2	rs117800443	A/G	0.0696	0.0221	0.0047	2.21E-06	22
SGLT2	rs45625038	T/C	0.0296	0.0413	0.0068	1.22E-09	34
SGLT2	rs4243236	C/G	0.0540	-0.0237	0.0051	3.84E-06	20
SGLT2	rs28692853	A/C	0.4926	-0.0145	0.0023	2.78E-10	36
SGLT2	rs116943658	A/G	0.3299	-0.0126	0.0025	3.01E-07	24
SGLT2	rs143816861	T/C	0.0181	-0.0412	0.0094	1.09E-05	21
SGLT2	rs9926717	G/A	0.2844	-0.0113	0.0026	9.61E-06	18
SGLT2	rs57794268	T/C	0.0663	0.0181	0.0046	8.76E-05	14
SGLT2	rs4411514	A/G	0.4429	-0.0112	0.0023	1.23E-06	21
SGLT2	rs2070896	C/T	0.3750	-0.0173	0.0024	1.7E-12	48
SGLT2	rs77819201	G/A	0.0270	0.0310	0.0073	2.27E-05	17
SGLT2	rs9929832	T/C	0.4738	-0.0091	0.0023	9.33E-05	14
SGLT2	rs8050328	G/T	0.3637	-0.0163	0.0024	1.1E-11	42
SGLT2	rs111510548	C/T	0.1034	-0.0152	0.0038	6.69E-05	15
SGLT2	rs45612043	C/A	0.0445	-0.0353	0.0056	2.51E-10	36
SGLT2	rs113947842	T/G	0.4066	-0.0110	0.0025	1.17E-05	20
SGLT2	rs28641848	T/C	0.2793	-0.0112	0.0026	1.21E-05	18
SGLT2	rs12932429	C/T	0.0497	-0.0252	0.0054	2.74E-06	21
SGLT2	rs149247820	T/C	0.0151	0.0433	0.0097	7.89E-06	19
SGLT2	rs145785014	T/C	0.0534	-0.0276	0.0052	9.23E-08	26
SGLT2	rs9924771	G/A	0.3482	-0.0116	0.0025	4.02E-06	21
SGLT2	rs11150620	C/G	0.3015	-0.0130	0.0025	2.9E-07	25
SGLT2	rs2454908	T/C	0.4354	-0.0098	0.0023	2.56E-05	16
SGLT2	rs8045738	G/T	0.3065	-0.0104	0.0025	2.94E-05	16
SGLT2	rs28675289	T/C	0.0444	-0.0382	0.0057	1.45E-11	43

It is made available under a [CC-BY 4.0 International license](#) .

SGLT2	rs3116150	A/G	0.2411	0.0136	0.0027	4.16E-07	23
SGLT2	rs8057207	T/C	0.3622	-0.0131	0.0024	4.55E-08	27
SGLT2	rs67464975	T/C	0.4699	-0.0117	0.0023	4.03E-07	24
SGLT2	rs9929691	T/C	0.1501	0.0155	0.0032	1.45E-06	21
DPP4	rs561174039	A/C	0.0205	-0.0364	0.0084	1.42E-05	18
DPP4	rs78818053	A/G	0.0306	-0.0287	0.0067	1.62E-05	17
GLP1R	rs61086156	G/C	0.0156	0.0372	0.0093	6.45E-05	15
GLP1R	rs10305420	T/C	0.3935	-0.0111	0.0024	2.96E-06	20
GLP1R	rs9462476	G/A	0.3246	-0.0137	0.0025	2.69E-08	28
GLP1R	rs1544935	G/T	0.2162	-0.0122	0.0028	1.37E-05	17
GLP1R	rs10305423	T/C	0.0337	-0.0286	0.0066	1.37E-05	18
GLP1R	rs1854961	A/C	0.4094	0.0097	0.0023	3.04E-05	16
GLP1R	rs10305518	G/T	0.0568	0.0289	0.0050	7.16E-09	31
GLP1R	rs57143316	C/T	0.0480	0.0294	0.0054	5.27E-08	27
GLP1R	rs10947785	A/G	0.4579	-0.0091	0.0023	8.04E-05	14
GLP1R	rs73731704	A/G	0.0581	0.0211	0.0049	1.8E-05	17
GLP1R	rs10305442	G/A	0.4671	0.0095	0.0023	4.23E-05	15
GLP1R	rs6929303	T/C	0.0536	0.0202	0.0051	7.66E-05	14
GLP1R	rs62688960	C/T	0.0322	-0.0265	0.0068	9.1E-05	15
GLP1R	rs12528717	T/A	0.0926	0.0186	0.0040	2.61E-06	20
GLP1R	rs10305457	T/C	0.0938	0.0218	0.0039	3.53E-08	28
GLP1R	rs6458097	T/C	0.4437	-0.0096	0.0023	3.58E-05	16
GLP1R	rs228824	C/T	0.3315	0.0114	0.0025	3.81E-06	20
GLP1R	rs56384501	A/G	0.3520	0.0104	0.0024	1.45E-05	17
GLP1R	rs56298410	T/C	0.0393	0.0275	0.0060	4.08E-06	20
GLP1R	rs9470964	G/A	0.0497	0.0277	0.0054	2.27E-07	25
GLP1R	rs112901579	T/C	0.0315	0.0275	0.0066	3.24E-05	16
GLP1R	rs77955327	C/A	0.0438	0.0285	0.0056	4.19E-07	23
GLP1R	rs9296291	C/T	0.2278	-0.0138	0.0028	5.27E-07	23
GLP1R	rs200781234	G/A	0.1074	0.0170	0.0037	5.09E-06	19
GLP1R	rs113120569	A/G	0.1686	0.0177	0.0031	9.53E-09	30

**Table 3. Characteristics of instrumental variables for each drug target in the HbA1c and prostate cancer datasets.** Chr, chromosome; EA/OA, effect allele/other allele; Pos, position.

Drug class	Proxy gene	SNP	Chr	Pos	EA/OA	Exposure (HbA1c)		Outcome (Prostate Cancer)	
						Beta	SE	Beta	SE
SGLT2 inhibitor	SGC5A2	rs111506	16	313921	C/G	-0.0130	0.0025	-0.0118	0.0094
		20		89					
		rs111510	16	314766	C/T	-0.0152	0.0038	-0.0223	0.0158
		548		95					
		rs113947	16	315485	T/G	-0.0110	0.0025	-0.0052	0.0092
		842		45					
		rs116943	16	314353	A/G	-0.0126	0.0025	-0.0159	0.0093
		658		66					
		rs117800	16	314824	A/G	0.0221	0.0047	0.0008	0.0202
		443		55					
		rs129324	16	314031	C/T	-0.0252	0.0054	0.0099	0.0188
		29		45					
		rs140154	16	313966	G/T	0.0457	0.0099	0.0623	0.0435
		847		67					
		rs143816	16	314617	T/C	-0.0412	0.0094	-0.0193	0.0309
861		21							
rs145785	16	315903	T/C	-0.0276	0.0052	-0.0211	0.0195		
014		26							
rs149247	16	315836	T/C	0.0433	0.0097	0.0660	0.0426		
820		95							
rs207089	16	313845	C/T	-0.0173	0.0024	-0.0201	0.0091		
6		54							
rs245490	16	314111	T/C	-0.0098	0.0023	-0.0033	0.0084		

Drug class	Proxy gene	SNP	Chr	Pos	EA/OA	Exposure (HbA1c)		Outcome (Prostate Cancer)	
						Beta	SE	Beta	SE
		8		85					
		rs286418	16	314551	T/C	-0.0112	0.0026	-0.0233	0.0096
		48		17					
		rs286752	16	314632	T/C	-0.0382	0.0057	-0.0111	0.0211
		89		52					
		rs286928	16	315730	A/C	-0.0145	0.0023	-0.0117	0.0083
		53		30					
		rs311615	16	314980	A/G	0.0136	0.0027	0.0131	0.0105
		0		21					
		rs424323	16	314674	C/G	-0.0237	0.0051	0.0039	0.0207
		6		44					
		rs441151	16	315849	A/G	-0.0112	0.0023	-0.0084	0.0085
		4		49					
		rs456120	16	314845	C/A	-0.0353	0.0056	-0.0135	0.0216
		43		98					
		rs456250	16	314189	T/C	0.0413	0.0068	0.0023	0.0335
		38		75					
		rs577942	16	315679	T/C	0.0181	0.0046	0.0005	0.0167
		68		42					
		rs674649	16	315442	T/C	-0.0117	0.0023	-0.0077	0.0082
		75		52					
		rs778192	16	313875	G/A	0.0310	0.0073	-0.0112	0.0281
		01		66					
		rs804573	16	314499	G/T	-0.0104	0.0025	-0.0099	0.0093
		8		98					
		rs805032	16	314044	G/T	-0.0163	0.0024	-0.0182	0.0090


Drug class	Proxy gene	SNP	Chr	Pos	EA/OA	Exposure (HbA1c)		Outcome (Prostate Cancer)	
						Beta	SE	Beta	SE
		8		67					
		rs805050	16	314045	C/T	-0.0266	0.0023	-0.0179	0.0089
		0		71					
		rs805720	16	315245	T/C	-0.0131	0.0024	-0.0221	0.0087
		7		80					
		rs992477	16	314955	G/A	-0.0116	0.0025	-0.0188	0.0093
		1		77					
		rs992671	16	314713	G/A	-0.0113	0.0026	-0.0269	0.0095
		7		78					
		rs992969	16	315521	T/C	0.0155	0.0032	0.0041	0.0110
		1		96					
		rs992983	16	313935	T/C	-0.0091	0.0023	0.0016	0.0086
		2		44					
DPP-IV inhibitor	DPP4	rs561174	2	162138	A/C	-0.0364	0.0025	0.0084	0.0328
		039		969					
		rs788180	2	162013	A/G	-0.0287	0.0038	0.0067	0.0254
		53		203					
GLP-1 agonists	GLP1R	rs103054	6	390166	T/C	-0.0111	0.0024	-0.0051	0.0085
		20		36					
		rs103054	6	390170	T/C	-0.0286	0.0066	0.0124	0.0356
		23		62					
		rs103054	6	390249	G/A	0.0095	0.0023	-0.0041	0.0084
		42		59					
		rs103054	6	390340	T/C	0.0218	0.0039	0.0137	0.0145
		57		95					
		rs103055	6	390550	G/T	0.0289	0.0050	0.0280	0.0189

Drug class	Proxy gene	SNP	Chr	Pos	EA/OA	Exposure (HbA1c)		Outcome (Prostate Cancer)	
						Beta	SE	Beta	SE
		18		12					
		rs109477	6	391328	A/G	-0.0091	0.0023	0.0189	0.0084
		85		18					
		rs112901	6	390829	T/C	0.0275	0.0066	-0.0472	0.0237
		579		42					
		rs113120	6	390373	A/G	0.0177	0.0031	0.0089	0.0110
		569		02					
		rs125287	6	390286	T/A	0.0186	0.0040	0.0119	0.0153
		17		06					
		rs154493	6	391244	G/T	-0.0122	0.0028	0.0300	0.0101
		5		48					
		rs185496	6	389624	A/C	0.0097	0.0023	-0.0037	0.0080
		1		45					
		rs200781	6	391011	G/A	0.0170	0.0037	-0.0150	0.0133
		234		22					
		rs228824	6	391119	C/T	0.0114	0.0025	-0.0083	0.0088
				69					
		rs562984	6	390740	T/C	0.0275	0.0060	-0.0447	0.0232
		10		12					
		rs563845	6	391211	A/G	0.0104	0.0024	-0.0207	0.0089
		01		43					
		rs571433	6	390692	C/T	0.0294	0.0054	-0.0253	0.0200
		16		91					
		rs610861	6	390593	G/C	0.0372	0.0093	0.0148	0.0332
		56		24					
		rs626889	6	391235	C/T	-0.0265	0.0068	-0.0194	0.0241

Drug class	Proxy gene	SNP	Chr	Pos	EA/OA	Exposure (HbA1c)		Outcome (Prostate Cancer)	
						Beta	SE	Beta	SE
		60		47					
		rs645809	6	391185	T/C	-0.0096	0.0023	0.0118	0.0085
		7		00					
		rs692930	6	391058	T/C	0.0202	0.0051	-0.0175	0.0179
		3		52					
		rs737317	6	391201	A/G	0.0211	0.0049	-0.0195	0.0182
		04		87					
		rs779553	6	390696	C/A	0.0285	0.0056	0.0342	0.0214
		27		99					
		rs929629	6	390569	C/T	-0.0138	0.0028	0.0104	0.0101
		1		29					
		rs946247	6	390709	G/A	-0.0137	0.0025	-0.0004	0.0089
		6		98					
		rs947096	6	390160	G/A	0.0277	0.0054	0.0155	0.0198
		4		96					




## Figures



**Figure 1. Estimated Effects of Genetic Variation in Antidiabetic Drug Targets on the risk of prostate cancer.**

Proxy gene is the gene that encodes the drug target proteins.  $P < 0.01$  indicates statistical significance, and  $0.01 < p < 0.05$  indicates suggestive significance.  $P$  for heterogeneity  $< 0.05$  indicates possible heterogeneity, whereas  $p$  for intercept  $< 0.05$  indicates substantial bias from pleiotropy. IVs, instrumental variables; SGLT2I, sodium-glucose cotransporter 2; DPP4I, dipeptidyl peptidase 4; GLP1a, glucagon-likepeptide 1; SNVs, single-nucleotide variations.



**Figure 2. Leave-one-out sensitivity analysis for genetically proxied SGLT2 inhibition on PCa.**

SGLT2, sodium-glucose cotransporter 2; PCa, Prostate cancer.

